FASN and breast carcinoma: In addition, the overexpression of FASN in adriamycin-resistant MCF7 breast cancer cells (MCF7/AdVp3000) has been suggested as a new target for chemoresistance and seems to be a poor prognosis indicator for breast cancer patients [40].